Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies

J Hepatol. 2022 Jul;77(1):9-11. doi: 10.1016/j.jhep.2022.04.020. Epub 2022 May 2.

Author

Marina Bárcena-Varela¹

Affiliation

¹ Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; The Precision Immunology Institute Department, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: marina.barcena-varela@mssm.edu.

PMID: 35513202
DOI: 10.1016/j.jhep.2022.04.020

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Carcinoma, Hepatocellular* / therapy
Humans
Immunotherapy
Liver Neoplasms* / therapy
Programmed Cell Death 1 Receptor

Substances

Programmed Cell Death 1 Receptor